Quest for Growth Founded 1999
Overview
Portfolio analytics
Team
Investments
News & Media
Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
info
The average size of a deal this fund participated in
$17M
Portfolio companies 21
Rounds per year 0.95
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 9
Stages of investment
Early Stage Venture
Late Stage Venture
Areas of investment
Biotechnology
Electronics
Health Care
Software
Telecommunications
Summary

Quest for Growth appeared to be the VC, which was created in 1999. The leading representative office of defined VC is situated in the Leuven. The venture was found in Europe in Belgium.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Quest for Growth, startups are often financed by BioMedPartners, Crescendo Ventures, VI Partners AG. The meaningful sponsors for the fund in investment in the same round are Capricorn Venture Partners, Gimv, Life Sciences Partners. In the next rounds fund is usually obtained by RUSNANO, Gimv, Kreos Capital.

Opposing the other organizations, this Quest for Growth works on 21 percentage points more the average amount of lead investments. The high activity for fund was in 2007. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2015.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - Belgium. Among the most popular portfolio startups of the fund, we may highlight Plastic Logic Germany, Kiadis Pharma, Miracor Medical. Among the most popular fund investment industries, there are Medical Device, Finance. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The overall number of key employees were 1.

Read more
Notable deals
CompanyIndustryRoundRound SizeDateInvestorsLocation
Sensolus
Information Services
Information Technology
Internet of Things
Wireless
Venture - Series Unknown
4M06 Oct 2020 Belgium, Ghent
Miracor Medical
Health Care
Health Diagnostics
Medical
Medical Device
Personal Health
Late Stage Venture
24M02 Sep 2020 Belgium, Awans
Miracor Medical
Health Care
Health Diagnostics
Medical
Medical Device
Personal Health
Late Stage Venture
5M04 Sep 2018 Belgium, Awans
HalioDx
Health Diagnostics
Medical
Pharmaceutical
Early Stage Venture
18M17 Jan 2018 France, Marseille
Sensolus
Information Services
Information Technology
Internet of Things
Wireless
Seed
3M12 Oct 2017 Belgium, Ghent
Sequana Medical
Biotechnology
Health Care
Manufacturing
Medical Device
Late Stage Venture
9M23 Oct 2015 Switzerland, Zurich
Kiadis Pharma
Biopharma
Biotechnology
Pharmaceutical
Venture - Series Unknown
10M20 Nov 2012 The Netherlands, Amsterdam
Prosonix
Biotechnology
Health Care
Pharmaceutical
Early Stage Venture
23M24 May 2012 United Kingdom, Oxford
Cartagenia
Genetics
Venture - Series Unknown
2M06 Oct 2011 Belgium, Leuven
Review
  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Quest for Growth?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: